Clinical trials: Intravitreal Injection
Proliferative Diabetic Retinopathy, Vitreous Hemorrhage
Pre- and Intra-operative Intravitreal Bevacizumab Injection in Diabetic Vitrectomy
The purpose of this study is to determine the effect of pre- and intra-operative bevacizumab injection on postoperative vitreous hemorrhage after diabetic vitrectomy.
- Trial name
- IBDV (NCT00745498)
- Testing
- Bevacizumab
- Where
- South Korea
- Volunteers
- 126 people
- Sponsor
- Seoul National University Bundang Hospital
Macular Degeneration
Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina.
In this clinical study researchers want to gain a deeper understanding of treatment consistence under real world conditions over the course of 24 months of Aflibercept injections into the eye for patients suffering from abnormal…
- Trial name
- ANDROMEDA (NCT03714308)
- Testing
- Ivt. Aflibercept (Eylea, BAY86-5321)
- Where
- Germany
- Volunteers
- 554 people
- Sponsor
- Bayer
Pain
Comparison of Patient Comfort After Two Anesthetic Protocols for Injections Into the Eye
Patient comfort during and after eye injections will be compared after two numbing (anesthetic) protocols, an eye preparation utilizing three cotton swabs soaked in 4% lidocaine drops versus a preparation using 3.5% lidocaine…
- Trial name
- NCT01087489
- Testing
- 4% lidocaine, 3.5% ophthalmic lidocaine gel
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Miami VA Healthcare System
Macular Edema, Central Retinal Vein Occlusion
Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
The present study provided additional efficacy and safety data for 0.5-mg ranibizumab using as needed (PRN) dosing over 24 months in patients with visual impairment due to macular edema secondary to Central Retinal Vein Occlusion…
- Trial name
- CRYSTAL (NCT01535261)
- Testing
- Ranibizumab 0.5 mg/0.05 ml
- Where
- 78 sites in Australia, Austria and 16 more
- Volunteers
- 357 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degeneration
Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects
To assess the safety and efficacy of repeated intravitreal injections of DE-122 (low dose and high dose) given in combination with Lucentis® in subjects with wet age-related macular degeneration (AMD) compared with Lucentis®…
- Trial name
- NCT03211234
- Testing
- 2.0 mg DE-122 Injectable Solution + Lucentis, 4.0 mg DE-122 Injectable Solution + Lucentis, Lucentis
- Where
- 14 sites in United States, Philippines
- Volunteers
- 76 people
- Sponsor
- Santen Inc.
Macular Degeneration
A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD
The purpose of this study is to determine the way and rate that the study medication, JSM6427 a potent, highly specific integrin α5β1-antagonist is absorbed, broken-down and eliminated from the body when it is given as a single…
- Trial name
- NCT00536016
- Testing
- JSM6427
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- Jerini Ophthalmic
Polypoidal Choroidal Vasculopathy
Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation
To evaluate the efficacy and safety of intravitreal aflibercept injection in the treatment of PCV
- Trial name
- EPIC (NCT01871376)
- Testing
- Intravitreal aflibercept injection 2.0mg
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Gregg T. Kokame, MD
Age-related Macular Degeneration
Study of PRN and Every 2months Intravitreal Aflibercept for Age Related Macular Degeneration
Evaluate a treatment result of every two months versus as needed (PRN) after 3 initial monthly intravitreal aflibercept for the Japanese age related macular degeneration.
- Trial name
- NCT01824225
- Testing
- Aflibercept
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Nihon University
Wet AMD, Macular Oedema
Intravitreal Bevacizumab for Retinal Disorders
Bevacizumab is an anti-VEGF agent used in approved for use in metastatic colorectal carcinoma (FDA Approved). This study analyzes the safety and efficacy of off-label Intravitreal Injection of bevacizumab (Avastin) for CNVM…
- Conditions
- Wet AMD, Macular Oedema, Proliferative Diabetic Retinopathy
- Trial name
- NCT00403026
- Testing
- Bevacizumab ( Avastin)
- Where
- India
- Volunteers
- 150 people
- Sponsor
- Narayana Nethralaya
Wet Macular Degeneration, Age-related Macular Degeneration
Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.
This study seeks to evaluate the effect of topical aqueous suppression on the anatomic and functional response to intravitreal anti-vascular endothelial growth factor (VEGF) injections in non-responders with wet age-related…
- Conditions
- Wet Macular Degeneration, Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT02571972
- Testing
- Dorzolamide-timolol
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Wills Eye
Diabetes Mellitus, Diabetic Retinopathy
Intravitreal Long Acting Gas in the Prevention of Early Postoperative Vitreous Hemorrhage in Diabetic Vitrectomy
Recurrent vitreous hemorrhage after vitrectomy for complications of diabetic retinopathy is a common occurrence. The hemorrhage may appear within the first few weeks after surgery or months later.
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Vitreous Hemorrhage
- Trial name
- NCT00155454
- Testing
- Intravitreal long acting gas (10% C3F8)
- Where
- Taiwan
- Volunteers
- 61 people
- Sponsor
- National Taiwan University Hospital
Diabetic Macular Edema
Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema
Currently, diabetic macular edema is treated is through injection of a medications such as off-label bevacizumab, which decreases the swelling in the retina.
- Trial name
- NCT02229175
- Testing
- bevacizumab, PASCAL Endpoint Management (EpM) laser treatment
- Where
- United States
- Sponsor
- University of California, San Francisco
Neovascular Age-related Macular Degeneration
An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD
This study was designed to evaluate a variable dosing regimen with intravitreal ranibizumab for the treatment of patients with neovascular age-related macular degeneration (AMD) in the Prospective OCT Imaging of Patients with…
- Trial name
- NCT00373659
- Testing
- Ranibizumab (Lucentis)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Miami
Leber Hereditary Optic Neuropathy
Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year
The goal of this clinical trial is to assess the efficacy and safety of GS010 gene therapy - (lenadogene nolparvovec) in subjects with LHON due to the G11778A ND4 mitochondrial mutation with a vision loss up to one year.
- Trial name
- REFLECT (NCT03293524)
- Testing
- GS010
- Where
- 13 sites in United States, Belgium and 5 more
- Volunteers
- 98 people
- Sponsor
- GenSight Biologics
Pattern Dystrophy of Macula
Intravitreal Aflibercept Injections In The Treatment Of Pattern Dystrophy
Adult-onset vitelliform detachments associated with pattern dystrophy is a genetic disorder that carries visual implications that most commonly affect the macula (area in the eye near the retina that is essential for sharp…
- Trial name
- AVA (NCT01965041)
- Testing
- aflibercept
- Where
- United States
- Sponsor
- Manhattan Eye, Ear & Throat Hospital
Non Infectious Uveitis
LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye
This is a Phase III study to assess the efficacy and safety of DE-109 440 µg every 2 months in subjects with active, non-infectious uveitis of the posterior segment of the eye (NIU-PS).
- Trial name
- NCT03711929
- Testing
- DE-109 Intravitreal Injections, DE-109 Intravitreal Injections (Open Label)
- Where
- 65 sites in United States, Argentina and 2 more
- Volunteers
- 145 people
- Sponsor
- Santen Inc.
Dry Age-related Macular Degeneration
Atrophic Age-related Macular Degeneration Treated With Intravitreal Injections of Umbilical Cord Blood Platelet-rich Plasma
The objective of the study will be to evaluate the efficacy of intravitreal injections of Umbilical Cord Blood Platelet-rich Plasma (CB-PRP) in order to reduce or stabilize the atrophic progression in dry Age-related Macular…
- Trial name
- CORD-IV (NCT05706896)
- Testing
- Intravitreal injection of CB-PRP
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cystoid Macular Edema, Uveitis
Study to Treat Uveitis Associated Macular Edema
The purpose of this study is to determine whether denufosol tetrasodium (INS37217) Intravitreal Injection is well tolerated and has the potential to treat uveitis associated macular edema.
- Trial name
- NCT00114062
- Testing
- denufosol tetrasodium (INS37217) Intravitreal Injection
- Volunteers
- 15 people
- Sponsor
- Merck Sharp & Dohme LLC